| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 17 | 2011 | 571 | 1.830 |
Why?
|
| Cord Blood Stem Cell Transplantation | 9 | 2017 | 89 | 1.550 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2018 | 779 | 1.340 |
Why?
|
| Arthritis, Rheumatoid | 11 | 2006 | 167 | 1.330 |
Why?
|
| Transplantation Conditioning | 12 | 2018 | 372 | 1.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2006 | 192 | 0.970 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2018 | 883 | 0.870 |
Why?
|
| Apoptosis | 13 | 2006 | 1705 | 0.830 |
Why?
|
| Neoplasm Proteins | 5 | 2006 | 539 | 0.760 |
Why?
|
| Synovial Membrane | 8 | 2006 | 28 | 0.740 |
Why?
|
| Enbucrilate | 2 | 2011 | 7 | 0.700 |
Why?
|
| Graft vs Host Disease | 8 | 2017 | 357 | 0.680 |
Why?
|
| Monocytes | 7 | 2011 | 217 | 0.680 |
Why?
|
| Mitoxantrone | 1 | 2018 | 68 | 0.610 |
Why?
|
| Cytarabine | 1 | 2018 | 219 | 0.590 |
Why?
|
| NF-kappa B | 8 | 2005 | 459 | 0.580 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 172 | 0.570 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2011 | 237 | 0.560 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2006 | 695 | 0.560 |
Why?
|
| Embolization, Therapeutic | 2 | 2011 | 251 | 0.550 |
Why?
|
| Hematologic Neoplasms | 3 | 2016 | 335 | 0.510 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2003 | 655 | 0.490 |
Why?
|
| Pharyngectomy | 1 | 2013 | 8 | 0.470 |
Why?
|
| Lasers, Solid-State | 1 | 2013 | 8 | 0.470 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 47 | 0.450 |
Why?
|
| Graft Survival | 4 | 2016 | 905 | 0.450 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 2392 | 0.440 |
Why?
|
| Cerebral Angiography | 2 | 2010 | 197 | 0.420 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 187 | 0.420 |
Why?
|
| Transplantation, Homologous | 11 | 2018 | 1000 | 0.420 |
Why?
|
| Cell Survival | 6 | 2011 | 977 | 0.420 |
Why?
|
| Gene Expression Regulation | 7 | 2008 | 1956 | 0.400 |
Why?
|
| Dextrans | 1 | 2011 | 77 | 0.400 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 37 | 0.390 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 64 | 0.390 |
Why?
|
| Biliopancreatic Diversion | 1 | 2010 | 4 | 0.380 |
Why?
|
| Induction Chemotherapy | 1 | 2011 | 149 | 0.380 |
Why?
|
| Aged | 21 | 2018 | 18750 | 0.370 |
Why?
|
| Fibroblasts | 6 | 2005 | 736 | 0.370 |
Why?
|
| Intestinal Absorption | 1 | 2010 | 124 | 0.370 |
Why?
|
| DNA-Binding Proteins | 6 | 2003 | 1224 | 0.360 |
Why?
|
| Humans | 50 | 2018 | 87949 | 0.360 |
Why?
|
| Middle Aged | 22 | 2018 | 25477 | 0.350 |
Why?
|
| Subtraction Technique | 1 | 2010 | 132 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2516 | 0.340 |
Why?
|
| Gastric Bypass | 1 | 2010 | 110 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 172 | 0.340 |
Why?
|
| Vertebral Artery Dissection | 1 | 2009 | 11 | 0.330 |
Why?
|
| Remission Induction | 3 | 2018 | 734 | 0.330 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2009 | 20 | 0.330 |
Why?
|
| Piperazines | 1 | 2010 | 278 | 0.330 |
Why?
|
| Brain Infarction | 1 | 2009 | 22 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 1347 | 0.310 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 137 | 0.310 |
Why?
|
| Pyrimidines | 1 | 2010 | 370 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2017 | 351 | 0.310 |
Why?
|
| Hemodynamics | 1 | 2011 | 723 | 0.310 |
Why?
|
| Fetal Blood | 4 | 2017 | 90 | 0.300 |
Why?
|
| Haplotypes | 3 | 2016 | 637 | 0.290 |
Why?
|
| Tissue Adhesives | 1 | 2007 | 23 | 0.290 |
Why?
|
| Synovial Fluid | 2 | 2005 | 10 | 0.290 |
Why?
|
| Adult | 17 | 2018 | 26131 | 0.280 |
Why?
|
| Recurrence | 5 | 2017 | 1168 | 0.280 |
Why?
|
| Mitochondria | 5 | 2006 | 545 | 0.280 |
Why?
|
| Immunotherapy | 1 | 2011 | 655 | 0.270 |
Why?
|
| Chimerism | 3 | 2016 | 36 | 0.270 |
Why?
|
| Treatment Outcome | 10 | 2018 | 8104 | 0.260 |
Why?
|
| Intracellular Membranes | 3 | 2006 | 117 | 0.260 |
Why?
|
| Survival Analysis | 6 | 2017 | 1539 | 0.260 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 4 | 2006 | 35 | 0.240 |
Why?
|
| Female | 22 | 2018 | 45399 | 0.240 |
Why?
|
| Phagocytes | 1 | 2004 | 10 | 0.240 |
Why?
|
| Synovitis | 1 | 2004 | 14 | 0.240 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 1144 | 0.240 |
Why?
|
| Brain Ischemia | 1 | 2009 | 402 | 0.240 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2004 | 9 | 0.240 |
Why?
|
| Vasculitis | 1 | 2004 | 39 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3425 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2000 | 33 | 0.230 |
Why?
|
| Male | 19 | 2018 | 41697 | 0.230 |
Why?
|
| Geriatric Assessment | 2 | 2015 | 181 | 0.230 |
Why?
|
| Trans-Activators | 2 | 2003 | 436 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2624 | 0.220 |
Why?
|
| Caspases | 7 | 2005 | 155 | 0.220 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1703 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2006 | 266 | 0.210 |
Why?
|
| Retrospective Studies | 7 | 2017 | 8780 | 0.200 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2004 | 383 | 0.190 |
Why?
|
| Membrane Glycoproteins | 4 | 2004 | 430 | 0.190 |
Why?
|
| Carrier Proteins | 6 | 2004 | 677 | 0.180 |
Why?
|
| STAT3 Transcription Factor | 3 | 2006 | 81 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 6655 | 0.170 |
Why?
|
| Young Adult | 9 | 2017 | 6151 | 0.170 |
Why?
|
| Unrelated Donors | 2 | 2017 | 44 | 0.170 |
Why?
|
| Antigens, CD34 | 3 | 2017 | 158 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2000 | 721 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 159 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 237 | 0.150 |
Why?
|
| Adolescent | 6 | 2017 | 9111 | 0.150 |
Why?
|
| Comorbidity | 4 | 2018 | 941 | 0.150 |
Why?
|
| HLA Antigens | 2 | 2016 | 226 | 0.150 |
Why?
|
| Cells, Cultured | 8 | 2006 | 2844 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2003 | 334 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2016 | 19 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 141 | 0.140 |
Why?
|
| Leukemia | 1 | 1999 | 321 | 0.140 |
Why?
|
| Azacitidine | 1 | 2017 | 139 | 0.140 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 2006 | 6 | 0.140 |
Why?
|
| Time Factors | 3 | 2011 | 5284 | 0.140 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.140 |
Why?
|
| Lipopolysaccharides | 5 | 2005 | 292 | 0.130 |
Why?
|
| Chromones | 3 | 2006 | 29 | 0.130 |
Why?
|
| Lymphoma | 1 | 2017 | 264 | 0.130 |
Why?
|
| Enzyme Activation | 5 | 2005 | 694 | 0.130 |
Why?
|
| Blood Donors | 1 | 2015 | 24 | 0.130 |
Why?
|
| Morpholines | 3 | 2006 | 67 | 0.130 |
Why?
|
| fas Receptor | 4 | 2004 | 76 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 64 | 0.130 |
Why?
|
| Sodium Salicylate | 2 | 2006 | 4 | 0.130 |
Why?
|
| Taiwan | 2 | 2011 | 23 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 107 | 0.130 |
Why?
|
| Donor Selection | 1 | 2015 | 73 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.130 |
Why?
|
| Cell Differentiation | 4 | 2008 | 1501 | 0.120 |
Why?
|
| Interleukin-6 | 4 | 2004 | 260 | 0.120 |
Why?
|
| Survival Rate | 2 | 2015 | 1877 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 297 | 0.120 |
Why?
|
| Consensus | 1 | 2015 | 349 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2015 | 358 | 0.110 |
Why?
|
| Cell Line | 3 | 2011 | 2491 | 0.110 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 27 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 381 | 0.110 |
Why?
|
| Transplantation Chimera | 1 | 2013 | 81 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 268 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2013 | 490 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2004 | 201 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 98 | 0.110 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2000 | 35 | 0.110 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 289 | 0.100 |
Why?
|
| Caspase 8 | 4 | 2005 | 34 | 0.100 |
Why?
|
| Mice | 7 | 2011 | 11619 | 0.100 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2011 | 4 | 0.100 |
Why?
|
| Neoplasms | 2 | 2018 | 2984 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2013 | 164 | 0.100 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2011 | 15 | 0.100 |
Why?
|
| Miniaturization | 1 | 2011 | 14 | 0.100 |
Why?
|
| Spectrophotometry | 1 | 2011 | 107 | 0.100 |
Why?
|
| Magnetite Nanoparticles | 1 | 2011 | 27 | 0.100 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 29 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2011 | 687 | 0.100 |
Why?
|
| Scattering, Radiation | 1 | 2011 | 116 | 0.100 |
Why?
|
| Incidence | 2 | 2015 | 1580 | 0.100 |
Why?
|
| Catheters | 1 | 2011 | 76 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 642 | 0.100 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 483 | 0.100 |
Why?
|
| Animals | 11 | 2011 | 27028 | 0.090 |
Why?
|
| I-kappa B Proteins | 2 | 2000 | 54 | 0.090 |
Why?
|
| Transfection | 4 | 2006 | 907 | 0.090 |
Why?
|
| Hospitalization | 1 | 2016 | 864 | 0.090 |
Why?
|
| Endocytosis | 1 | 2011 | 177 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 126 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 858 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2004 | 309 | 0.090 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 340 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 153 | 0.090 |
Why?
|
| Equipment Design | 1 | 2011 | 415 | 0.090 |
Why?
|
| Intestinal Diseases | 1 | 2010 | 79 | 0.090 |
Why?
|
| Illinois | 1 | 2011 | 465 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2011 | 162 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1079 | 0.090 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 76 | 0.090 |
Why?
|
| Benzamides | 1 | 2010 | 236 | 0.090 |
Why?
|
| Contrast Media | 2 | 2011 | 1084 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 838 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2011 | 162 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2010 | 226 | 0.080 |
Why?
|
| Inflammation | 2 | 2005 | 951 | 0.080 |
Why?
|
| Fas Ligand Protein | 3 | 2004 | 49 | 0.080 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2009 | 16 | 0.080 |
Why?
|
| Vertebral Artery | 1 | 2009 | 23 | 0.080 |
Why?
|
| Caspase 9 | 3 | 2004 | 48 | 0.080 |
Why?
|
| Neutrophils | 2 | 2016 | 307 | 0.080 |
Why?
|
| Membrane Potentials | 3 | 2006 | 436 | 0.080 |
Why?
|
| Adenoviridae | 4 | 2003 | 347 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2011 | 861 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1209 | 0.080 |
Why?
|
| Prognosis | 2 | 2018 | 3729 | 0.080 |
Why?
|
| Carotid Artery, Internal | 1 | 2009 | 69 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 888 | 0.080 |
Why?
|
| Interleukin-1 | 2 | 2005 | 71 | 0.080 |
Why?
|
| Arthritis, Experimental | 3 | 2004 | 26 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 147 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 138 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1939 | 0.070 |
Why?
|
| Fatty Acids | 1 | 2008 | 131 | 0.070 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2007 | 10 | 0.070 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 33 | 0.070 |
Why?
|
| Hemostasis | 1 | 2007 | 21 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2001 | 951 | 0.070 |
Why?
|
| Caspase 3 | 2 | 2004 | 160 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2006 | 23 | 0.070 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 138 | 0.070 |
Why?
|
| Steroids | 1 | 2008 | 175 | 0.070 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 198 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 425 | 0.070 |
Why?
|
| Adenosine Diphosphate | 1 | 2006 | 55 | 0.070 |
Why?
|
| Base Sequence | 2 | 2001 | 2333 | 0.070 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2004 | 115 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 299 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1827 | 0.070 |
Why?
|
| Necrosis | 1 | 2006 | 208 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2004 | 225 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2009 | 420 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 696 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 314 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 810 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 286 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 555 | 0.060 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2004 | 11 | 0.060 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2004 | 21 | 0.060 |
Why?
|
| Obesity | 1 | 2010 | 957 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2004 | 83 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 90 | 0.060 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 16 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2006 | 3331 | 0.060 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2003 | 17 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2003 | 109 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 167 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2004 | 126 | 0.050 |
Why?
|
| Cyclins | 1 | 2003 | 83 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 993 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2002 | 32 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 102 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 235 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2002 | 65 | 0.050 |
Why?
|
| Homeostasis | 2 | 2001 | 406 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 5405 | 0.050 |
Why?
|
| Transgenes | 1 | 2002 | 181 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2002 | 90 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 1414 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2001 | 16 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2001 | 33 | 0.050 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 9 | 0.050 |
Why?
|
| Serpins | 1 | 2001 | 30 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2000 | 86 | 0.050 |
Why?
|
| DNA Primers | 1 | 2001 | 544 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2003 | 1121 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2014 | 4247 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2000 | 49 | 0.050 |
Why?
|
| Genetic Vectors | 4 | 2003 | 442 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2002 | 354 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2001 | 726 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2000 | 42 | 0.040 |
Why?
|
| Disease Progression | 2 | 2016 | 1479 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2001 | 300 | 0.040 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 3 | 2004 | 13 | 0.040 |
Why?
|
| Growth Substances | 1 | 1999 | 80 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 92 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1697 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 1999 | 353 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 279 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 55 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 97 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2000 | 338 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2000 | 415 | 0.040 |
Why?
|
| Child | 1 | 2009 | 7065 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 270 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1049 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2000 | 544 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2006 | 5 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 2802 | 0.030 |
Why?
|
| Protein Binding | 1 | 2000 | 1476 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 34 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 222 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 24 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 2061 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 136 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 174 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 136 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2005 | 91 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1247 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 3028 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2006 | 53 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 610 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 65 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 96 | 0.030 |
Why?
|
| Fas-Associated Death Domain Protein | 2 | 2004 | 7 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2004 | 1996 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2013 | 59 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 96 | 0.030 |
Why?
|
| Rats, Inbred Lew | 2 | 2002 | 191 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2000 | 1622 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 2 | 2003 | 65 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 68 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2011 | 111 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 122 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 85 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2011 | 116 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2000 | 42 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1853 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 156 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 384 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 990 | 0.020 |
Why?
|
| Critical Care | 1 | 2011 | 373 | 0.020 |
Why?
|
| Mitochondrial ADP, ATP Translocases | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2006 | 8 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2006 | 25 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2006 | 53 | 0.020 |
Why?
|
| Permeability | 1 | 2006 | 137 | 0.020 |
Why?
|
| Rats | 2 | 2002 | 4022 | 0.020 |
Why?
|
| Cysteine | 1 | 2006 | 136 | 0.020 |
Why?
|
| Biological Transport | 1 | 2006 | 399 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 506 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2004 | 20 | 0.020 |
Why?
|
| Cell Death | 1 | 2006 | 261 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 63 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3650 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 6b | 1 | 2003 | 1 | 0.010 |
Why?
|
| Adenoviridae Infections | 1 | 2003 | 17 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 25 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 92 | 0.010 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2003 | 14 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2003 | 10 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 41 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 794 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 78 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 67 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 73 | 0.010 |
Why?
|
| Hindlimb | 1 | 2002 | 92 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 152 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 122 | 0.010 |
Why?
|
| Proton-Motive Force | 1 | 2000 | 1 | 0.010 |
Why?
|
| Replication Protein C | 1 | 2000 | 2 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 513 | 0.010 |
Why?
|
| Thiocarbamates | 1 | 2000 | 6 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 42 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 41 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2000 | 39 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2003 | 506 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 78 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2000 | 137 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 2000 | 59 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 292 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 322 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2002 | 440 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 353 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 1969 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 2513 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1299 | 0.010 |
Why?
|
| Skin | 1 | 2000 | 570 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 2317 | 0.010 |
Why?
|